Critical reagent considerations for immunogenicity assay development for bispecific biotherapeutic candidates

Arkadeep Sinhaa Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA01821, USA;d Upstream Bio, 460 Totten Pond Rd. Suite 420, Waltham, MA02451, USAView further author information

Sherri Rinkerb B2S Life Sciences, 97 East Monroe Street, Franklin, IN46131, USAView further author information

Mallory Rose Souliotisa Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA01821, USA;e Bioagilytix, 1320 Soldiers Field Rd, Boston, MA02135, USAView further author information

Rajesh Kumara Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA01821, USAView further author information

Seema Kumara Clinical Bioanalytical Sciences, EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA01821, USA;f Pioneering Medicines at Flagship Pioneering, 140 First St, Cambridge, MA02141, USA

https://orcid.org/0000-0002-6845-3941 View further author information

Kyra J Cowanc Merck Healthcare KGaA, Frankfurter Str. 250, Postcode D50/225, 64293, Darmstadt, GermanyCorrespondence[email protected]
View further author information

Critical reagent considerations for immunogenicity assay development for bispecific biotherapeutic candidates

Supplementary Figures S1-S7

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Critical reagent considerations for immunogenicity assay development for bispecific biotherapeutic candidates

Supplementary Figures S1-S7

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date